Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A Functional Immune System Is Required for the Systemic Genotoxic Effects of Localized Irradiation.

Lobachevsky PN, Ventura J, Giannakandropoulou L, Forrester H, Palazzolo JS, Haynes NM, Stevenson AW, Hall CJ, Mason J, Pollakis G, Pateras IS, Gorgoulis V, Terzoudi GI, Hamilton JA, Sprung CN, Georgakilas AG, Martin OA.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1184-1193. doi: 10.1016/j.ijrobp.2018.11.066. Epub 2018 Dec 6.

PMID:
30529375
2.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

3.

Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.

Hammond E, Haynes NM, Cullinane C, Brennan TV, Bampton D, Handley P, Karoli T, Lanksheer F, Lin L, Yang Y, Dredge K.

J Immunother Cancer. 2018 Jun 14;6(1):54. doi: 10.1186/s40425-018-0363-5.

4.

Localized Synchrotron Irradiation of Mouse Skin Induces Persistent Systemic Genotoxic and Immune Responses.

Ventura J, Lobachevsky PN, Palazzolo JS, Forrester H, Haynes NM, Ivashkevich A, Stevenson AW, Hall CJ, Ntargaras A, Kotsaris V, Pollakis GC, Potsi G, Skordylis K, Terzoudi G, Pateras IS, Gorgoulis VG, Georgakilas AG, Sprung CN, Martin OA.

Cancer Res. 2017 Nov 15;77(22):6389-6399. doi: 10.1158/0008-5472.CAN-17-1066. Epub 2017 Nov 7.

5.

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM.

Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1.

6.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK.

Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12.

7.

A community-based model of rapid autopsy in end-stage cancer patients.

Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, Devereux L, O'Brien P, Gunawardena S, Hampson C, Strachan K, Jaravaza RD, Francis V, Young G, Ranson D, Samaranayake R, Stevens D, Boyle S, Fedele C, Topp M, Ho G, Teo ZL, Taylor RA, Papargiris MM, Lawrence MG, Wang H, Risbridger GP, Haynes NM, Medon M, Johnstone RW, Vidacs E, Arnau GM, Vergara IA, Papenfuss AT, McArthur G, Waring P, Carvosso S, Angel C, Gyorki D, Solomon B, Mitchell G, Shanley S, Francis PA, Dawson SJ, Haffenden A, Tidball E, Volchek M, Pyman J, Madadin M, Leditschke J, Cordner S; Melbourne Melanoma Project; Australian Ovarian Cancer Study Group (AOCS); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Shackleton M, Bowtell DD.

Nat Biotechnol. 2016 Oct;34(10):1010-1014. doi: 10.1038/nbt.3674. Epub 2016 Sep 12. No abstract available.

PMID:
27617737
8.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.

J Clin Invest. 2016 Jan;126(1):402-3. doi: 10.1172/JCI84828. Epub 2015 Nov 23. No abstract available.

9.

Lethal giant larvae-1 deficiency enhances the CD8(+) effector T-cell response to antigen challenge in vivo.

Ramsbottom KM, Sacirbegovic F, Hawkins ED, Kallies A, Belz GT, Van Ham V, Haynes NM, Durrant MJ, Humbert PO, Russell SM, Oliaro J.

Immunol Cell Biol. 2016 Mar;94(3):306-11. doi: 10.1038/icb.2015.82. Epub 2015 Sep 22.

PMID:
26391810
10.

Building immunity to cancer with radiation therapy.

Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM.

Cancer Lett. 2015 Nov 28;368(2):198-208. doi: 10.1016/j.canlet.2015.01.009. Epub 2015 Jan 12. Review.

PMID:
25592036
11.

The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling.

Verbrugge I, Gasparini A, Haynes NM, Hagekyriakou J, Galli M, Stewart TJ, Abrams SI, Yagita H, Verheij M, Johnstone RW, Borst J, Neefjes J.

Radiat Res. 2014 Aug;182(2):219-29. doi: 10.1667/RR13511.1. Epub 2014 Jun 24. Erratum in: Radiat Res. 2014 Oct;182(4):e45.

PMID:
24960417
12.

Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation.

Kansara M, Leong HS, Lin DM, Popkiss S, Pang P, Garsed DW, Walkley CR, Cullinane C, Ellul J, Haynes NM, Hicks R, Kuijjer ML, Cleton-Jansen AM, Hinds PW, Smyth MJ, Thomas DM.

J Clin Invest. 2013 Dec;123(12):5351-60. doi: 10.1172/JCI70559. Epub 2013 Nov 15.

13.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.

Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.

14.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.

J Clin Invest. 2013 Mar;123(3):1371-81. doi: 10.1172/JCI66236. Epub 2013 Feb 1. Erratum in: J Clin Invest. 2013 Jul 1;123(7):3182. J Clin Invest. 2016 Jan;126(1):402-3.

15.

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies.

Verbrugge I, Galli M, Smyth MJ, Johnstone RW, Haynes NM.

Oncoimmunology. 2012 Dec 1;1(9):1629-1631.

16.

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, Haynes NM.

Cancer Res. 2012 Jul 1;72(13):3163-74. doi: 10.1158/0008-5472.CAN-12-0210. Epub 2012 May 8.

17.

Immunotherapeutic strategies as adjuncts to local radiotherapy.

Haynes NM, Smyth MJ.

Immunotherapy. 2012 Feb;4(2):129-31. doi: 10.2217/imt.11.155. No abstract available.

PMID:
22339453
18.

A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells.

Hoves S, Sutton VR, Haynes NM, Hawkins ED, Fernández Ruiz D, Baschuk N, Sedelies KA, Schnurr M, Stagg J, Andrews DM, Villadangos JA, Trapani JA.

J Immunol. 2011 Aug 1;187(3):1166-75. doi: 10.4049/jimmunol.1001670. Epub 2011 Jun 27.

19.

Effects of neurofibromatosis type 1 on children's development.

Haynes NM, Kirwan JR, McCrohan K.

Soc Work Public Health. 2011;26(4):444-53. doi: 10.1080/19371918.2011.579498.

PMID:
21707352
20.

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4141-6. doi: 10.1073/pnas.1011037108. Epub 2011 Feb 22.

21.

Generation of chimeric T-cell receptor transgenes and their efficient transfer in primary mouse T lymphocytes.

Howland LJ, Haynes NM, Darcy PK.

Methods Mol Biol. 2010;651:291-306. doi: 10.1007/978-1-60761-786-0_17.

PMID:
20686973
22.

CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.

Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hämmerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK, Smyth MJ.

J Immunol. 2010 Jul 1;185(1):532-41. doi: 10.4049/jimmunol.0903624. Epub 2010 May 26.

23.

Chemotherapy and radiotherapy: cryptic anticancer vaccines.

Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L.

Semin Immunol. 2010 Jun;22(3):113-24. doi: 10.1016/j.smim.2010.03.001. Epub 2010 Apr 18. Review.

PMID:
20403709
24.

Characterizing the anti-tumor function of adoptively transferred NK cells in vivo.

Pegram HJ, Haynes NM, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Immunol Immunother. 2010 Aug;59(8):1235-46. doi: 10.1007/s00262-010-0848-7. Epub 2010 Apr 8.

PMID:
20376439
25.

Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice.

Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, Smyth MJ, Darcy PK, Kershaw MH.

Clin Cancer Res. 2009 Dec 15;15(24):7624-7633.

26.

Membrane-bound Fas ligand only is essential for Fas-induced apoptosis.

O' Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A.

Nature. 2009 Oct 1;461(7264):659-63. doi: 10.1038/nature08402.

27.

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L.

Nat Med. 2009 Oct;15(10):1170-8. doi: 10.1038/nm.2028. Epub 2009 Sep 20.

PMID:
19767732
28.

The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum.

Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileshkin L, Ball D, Michael M, Burman A, Mayura-Guru P, Trapani JA, Peinert S, Hönemann D, Miles Prince H, Scott AM, Smyth MJ, Darcy PK, Kershaw MH.

J Immunother. 2009 Apr;32(3):292-301. doi: 10.1097/CJI.0b013e31819b7c8e.

PMID:
19242371
29.

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors.

Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M.

J Exp Med. 2008 Dec 22;205(13):2965-73. doi: 10.1084/jem.20081752. Epub 2008 Nov 24.

30.

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.

Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P, Stanley K, Bolden JE, Takeda K, Yagita H, Secrist JP, Smyth MJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11317-22. doi: 10.1073/pnas.0801868105. Epub 2008 Aug 6.

31.

Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.

Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K, Aoyama T, Frese S, Ikeda H, Haynes NM, Cretney E, Yagita H, Sueyoshi N, Sato N, Nakanuma Y, Smyth MJ, Okumura K.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10895-900. doi: 10.1073/pnas.0802702105. Epub 2008 Jul 30.

32.

Immunogenic anti-cancer chemotherapy as an emerging concept.

Haynes NM, van der Most RG, Lake RA, Smyth MJ.

Curr Opin Immunol. 2008 Oct;20(5):545-57. doi: 10.1016/j.coi.2008.05.008. Epub 2008 Jun 23. Review.

PMID:
18573339
33.

Interleukin 21 enhances antibody-mediated tumor rejection.

Smyth MJ, Teng MW, Sharkey J, Westwood JA, Haynes NM, Yagita H, Takeda K, Sivakumar PV, Kershaw MH.

Cancer Res. 2008 Apr 15;68(8):3019-25. doi: 10.1158/0008-5472.CAN-07-6019.

34.

Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.

Westwood JA, Murray WK, Trivett M, Shin A, Neeson P, MacGregor DP, Haynes NM, Trapani JA, Mayura-Guru P, Fox S, Peinert S, Honemann D, Prince HM, Ritchie D, Scott AM, Smyth FE, Smyth MJ, Darcy PK, Kershaw MH.

Gene Ther. 2008 Jul;15(14):1056-66. doi: 10.1038/gt.2008.47. Epub 2008 Mar 27.

PMID:
18369322
35.

Follicular associated T cells and their B-cell helper qualities.

Haynes NM.

Tissue Antigens. 2008 Feb;71(2):97-104. doi: 10.1111/j.1399-0039.2007.00995.x. Review.

PMID:
18201361
36.
37.

Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism.

Kabashima K, Haynes NM, Xu Y, Nutt SL, Allende ML, Proia RL, Cyster JG.

J Exp Med. 2006 Nov 27;203(12):2683-90. Epub 2006 Nov 13.

38.

Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.

Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MW, Street SE, Cerutti L, Jane SM, Trapani JA, Smyth MJ, Darcy PK.

Blood. 2005 Nov 1;106(9):2995-3003. Epub 2005 Jul 19.

PMID:
16030195
39.

Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.

Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, Smyth MJ, Darcy PK.

J Immunol. 2004 Aug 1;173(3):2143-50.

40.

A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.

Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Cancer Gene Ther. 2004 May;11(5):371-9.

PMID:
15060573
41.

Addressing students' social and emotional needs: the role of mental health teams in schools.

Haynes NM.

J Health Soc Policy. 2002;16(1-2):109-23. Review.

PMID:
12809382
42.

Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

J Immunol. 2002 Nov 15;169(10):5780-6. Erratum in: J Immunol. 2003 Mar 15;170(6):3440.

43.

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.

Blood. 2002 Nov 1;100(9):3155-63. Erratum in: Blood. 2003 May 15;101(10):3808.

PMID:
12384413
44.
45.

Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL.

Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ.

J Immunol. 2000 Apr 1;164(7):3705-12.

46.

Multiple deficiencies underlie NK cell inactivity in lymphotoxin-alpha gene-targeted mice.

Smyth MJ, Johnstone RW, Cretney E, Haynes NM, Sedgwick JD, Korner H, Poulton LD, Baxter AG.

J Immunol. 1999 Aug 1;163(3):1350-3.

47.

Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes.

Haynes NM, Smyth MJ, Kershaw MH, Trapani JA, Darcy PK.

Cancer Immunol Immunother. 1999 Jan;47(5):278-86.

PMID:
10022472
48.

Promoting holistic child development: a collaborative school health approach.

Haynes NM.

J Sch Health. 1998 Nov;68(9):381-3. Review. No abstract available.

PMID:
9854695
49.

The effects of a school development program on self-concept.

Haynes NM, Comer JP.

Yale J Biol Med. 1990 Jul-Aug;63(4):275-83.

50.

Influence of self-concept on school adjustment among middle-school students.

Haynes NM.

J Soc Psychol. 1990 Apr;130(2):199-207.

PMID:
2342347

Supplemental Content

Loading ...
Support Center